The massive resale registration (57.9% overhang) combined with a Q1 earnings miss creates strong near-term selling pressure. Monitor for actual sales by insiders; the registration becomes effective shortly. Consider short-term bearish bias until the overhang clears or a substantial portion is sold.
Price Chart
Executive Summary
Jade Biosciences filed an S-3 resale registration for up to 39.5M shares held by selling stockholders (57.9% of outstanding), including entities affiliated with Fairmount, Fidelity, and RA Capital. The company will receive no proceeds. This filing coincides with a Q1 2026 earnings miss (EPS -$0.57 vs -$0.52 consensus) and widening net loss ($40.4M). The massive potential overhang creates significant downward pressure on the stock.
Key Facts
- Registers 39,542,339 shares for resale by selling stockholders, representing ~57.9% of shares outstanding as of March 15, 2026
- Company will not receive any proceeds from the resale; only nominal exercise proceeds from pre-funded warrants
- Q1 2026 EPS of -$0.57 missed consensus of -$0.52 by 9.6%; net loss widened to $40.4M from $38.2M YoY
- R&D spend increased 80% YoY to $36.1M; cash burn continues ($311M vs $336M in Dec 2025)
- Large insider selling overhang from PIPE investors including Fairmount (22.97M shares), Fidelity, RA Capital, Janus, Baker Bros
Financial Impact
Up to $489.7M in shares (at $23.57 per share) could be sold by selling stockholders; no proceeds to company
Risk Factors
- Significant stock price decline from actual or perceived selling by large holders
- Widening losses and cash burn without near-term revenue catalysts
- Further dilution if additional equity raises are needed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-212443 |
| Document: d149521dexfilingfees.htm | 0001193125-26-212443 |
| Document: d149521dex51.htm | 0001193125-26-212443 |
| Document: d149521dex231.htm | 0001193125-26-212443 |
| Document: 0001193125-26-212443-index-headers.html | 0001193125-26-212443 |
| Document: 0001193125-26-212443-index.html | 0001193125-26-212443 |
| Document: 0001193125-26-212443.txt | 0001193125-26-212443 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $14.52 | awaiting T+5 | — | $14.74 (+1.52%) |
Sep 30, 2026 27d ago | 8-K | $14.05 $13.77 | ▼ −1.99% | ▼ −3.91% | $14.74 (+4.91%) |
Aug 10, 2026 11w ago | 8-K | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.74 (−32.17%) |
Aug 10, 2026 11w ago | Press Release | $21.73 $23.45 | ▲ +7.92% | ▲ +7.96% | $14.74 (−32.17%) |
Jun 5, 2026 20w ago | Press Release | $14.98 $16.10 | ▼ −7.48% | ▼ −5.37% | $14.74 (+1.60%) |
Jun 4, 2026 20w ago | 8-K | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.74 (+12.99%) |
Jun 4, 2026 20w ago | 424B5 | $16.94 $15.34 | ▲ +9.45% | ▲ +10.01% | $14.74 (+12.99%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
Jun 3, 2026 20w ago | 424B5 | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
Jun 3, 2026 20w ago | Press Release | $17.74 $16.08 | ▲ +9.36% | ▲ +6.80% | $14.74 (+16.91%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers